Welcome to our dedicated page for Novo-Nordisk A/S news (Ticker: NVO), a resource for investors and traders seeking the latest updates and insights on Novo-Nordisk A/S stock.
Novo Nordisk A/S (NVO) generates a steady stream of news across diabetes, obesity, rare disease, and cardiometabolic medicine. As a Denmark‑based global healthcare company with B shares listed on Nasdaq Copenhagen and ADRs on the NYSE, its announcements often cover regulatory milestones, clinical trial data, pricing and access initiatives, and strategic corporate actions.
A major focus of recent news is Wegovy (semaglutide), Novo Nordisk’s GLP‑1 therapy for weight management and cardiometabolic risk reduction. Press releases describe FDA approvals for Wegovy injection 2.4 mg in obesity, cardiovascular risk reduction, and metabolic dysfunction‑associated steatohepatitis (MASH), as well as the approval of the once‑daily Wegovy pill, the first oral GLP‑1 medicine for weight management in the US. News coverage also highlights patient access programs, savings offers, and the launch of NovoCare Pharmacy to provide direct‑to‑patient delivery of authentic, FDA‑approved Wegovy.
Investors following NVO news will also see updates on CagriSema and other pipeline assets, including phase 3 data in obesity and cardiovascular risk factors, acquisitions in MASH and rare blood disorders, and broader R&D pipeline progress reported in the company’s financial updates. Corporate governance developments, such as the convening of an Extraordinary General Meeting to elect new board members, and disclosures of share transactions by executives and board members, are reported through Form 6‑K filings.
This news page aggregates these company announcements, clinical and regulatory updates, pricing and access changes, and governance disclosures related to Novo Nordisk A/S. For readers tracking NVO, it provides a focused view of how the company is advancing GLP‑1 therapies, expanding its obesity and cardiometabolic franchise, and managing its global operations and capital markets presence over time.
Novo Nordisk (NYSE:NVO) announced that Wegovy pill (semaglutide), the first oral GLP-1 for adult weight loss, was approved Dec 22, 2025 and is now broadly available across the US via 70,000+ pharmacies and select telehealth providers.
In the OASIS 4 trial Wegovy pill 25 mg showed an average weight reduction of about 17% at 64 weeks if all patients stayed on treatment and about 14% regardless of treatment persistence versus ~3% and ~2% for placebo. Starter pricing begins at $149/month ($5/day) with insured patients paying as little as $25/month.
Novo Nordisk (NVO) presented post hoc REDEFINE 1 analyses at ObesityWeek (Nov 6, 2025) showing investigational CagriSema (2.4 mg/2.4 mg) reduced systolic blood pressure by 10.9 mmHg versus 8.8 mmHg for semaglutide 2.4 mg and 2.1 mmHg for placebo over 68 weeks.
CagriSema allowed ~40% of participants on antihypertensives to reduce or stop medication and lowered hsCRP by 68.9% (versus 55.4% semaglutide, 16.0% placebo). Safety was consistent with the GLP-1 RA class; gastrointestinal adverse events were more frequent with CagriSema.
Novo Nordisk (NYSE:NVO) has received FDA approval for Wegovy® (semaglutide) 2.4 mg injection to treat adults with noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis) with moderate to advanced liver fibrosis. This marks a significant milestone as Wegovy® becomes the first GLP-1 RA approved for MASH treatment.
The approval is based on the Phase 3 ESSENCE trial results, which showed that 63% of Wegovy®-treated patients achieved steatohepatitis resolution compared to 34% on placebo, and 37% showed liver fibrosis improvement versus 22% on placebo. The drug demonstrated strong efficacy with 83.5% of patients maintaining the target dose through Week 72.
This represents Wegovy's fourth FDA-approved indication, following its previous approvals for obesity management, cardiovascular risk reduction, and pediatric obesity treatment. Novo Nordisk has also submitted regulatory applications in the EU and Japan.
Novo Nordisk (NYSE:NVO) has announced a new collaboration with WeightWatchers to expand patient access to FDA-approved Wegovy® starting July 1, 2025. The partnership aims to provide patients with streamlined access to the weight management drug through CenterWell Pharmacy.
The company is introducing a new $299 savings offer for self-paying patients from July 1-31, 2025, following the expiration of their previous $199 offer. After July, the price will increase to $499 per month. The offer will be available through WeightWatchers, Ro, LifeMD, and NovoCare® Pharmacy.
Additionally, Novo Nordisk continues its efforts against illegal knockoff "semaglutide" drugs, having filed nearly 120 lawsuits across 34 states. The company warns about risks associated with compounded versions, particularly those using ingredients from unauthorized Chinese suppliers.
Novo Nordisk has expanded its Wegovy® savings program, now offering the weight management medication at $499 per month to eligible cash-paying patients across all dose strengths (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg) at local retail pharmacies. Previously, this pricing was only available through the NovoCare® Pharmacy.
This expansion aims to improve accessibility and affordability while ensuring patients receive authentic, FDA-approved Wegovy® from reputable pharmacies, addressing concerns about risks associated with the compounding marketplace. The program reinforces Novo Nordisk's commitment to making innovative medicines more accessible to communities they serve.
Novo Nordisk has launched NovoCare® Pharmacy, offering all doses of Wegovy® (semaglutide) at a reduced cost of $499 per month for cash-paying patients, with convenient home delivery service. This initiative follows FDA's confirmation that the medicine's shortage is resolved, with supply meeting current and projected U.S. demand.
The program targets uninsured patients or those with commercial insurance lacking obesity medicine coverage. Currently, 90% of Wegovy® patients with coverage pay $0 to $25 monthly. The service includes home shipments through CenterWell Pharmacy, benefit verification, refill reminders, and live support from NovoCare® case managers.
The initiative aims to provide reliable access to authentic, FDA-approved Wegovy® amid concerns about fake or illegitimate compounded semaglutide. Novo Nordisk plans to extend this reduced pricing to cash-paying patients using traditional retail pharmacies in the future.
Novo Nordisk has launched a national campaign called The Power of Wegovy® to highlight the effectiveness of Wegovy® (semaglutide) 2.4 mg injection for weight management and cardiovascular risk reduction. The campaign aims to educate the public on the clinical benefits and safety of Wegovy® while addressing the stigma associated with obesity. The FDA-approved drug is used alongside a reduced-calorie diet and increased physical activity to aid weight loss and reduce major cardiovascular events in adults with heart disease. A recent FDA update has expanded its indications, and Novo Nordisk is working to improve drug access and insurance coverage.
FAQ
What is the current stock price of Novo-Nordisk A/S (NVO)?
What is the market cap of Novo-Nordisk A/S (NVO)?
